<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481637</url>
  </required_header>
  <id_info>
    <org_study_id>RDA-0269</org_study_id>
    <nct_id>NCT00481637</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients</brief_title>
  <official_title>Tumor Immunity in Neurologically Normal Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study whether immune cells capable of killing tumors that
      express proteins associated with paraneoplastic neurologic syndrome (PNS) can be found in
      small cell lung cancer and ovarian cancer patients. The presence of these cells may play a
      role in tumor immunity in these patients. The protocol involves neurological examinations and
      collection of blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief description
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Paraneoplastic neoplastic disease antibody titer, Cytotoxic T Lymphocyte activity, and clinical data in neurologically normal patients with small cell lung cancer and gynecologic tumors, with tumors unrelated to PNDs, and in normal control patients.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <description>SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Normal volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with SCLC and gynecologic (breast or ovarian) tumors and patients with unrelated
        cancers. Also healthy volunteers will be included as a comparison group in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ages 25 -75

          2. If leukapheresis:

             Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if
             tested* HIV antibody negative if tested* Venereal disease reaction level (VDRL)
             negative if tested* No known IV drug users Hemoglobin &gt; 8.5 White blood cell count &gt;
             3,800 Platelets &gt; 120,000 International normalized ratio (INR) &lt; 2 (verified only if
             clinically indicated)

          3. If large blood draw (1/2 to 1 unit) in lieu of leukapheresis:

        Hepatitis B surface antigen negative if tested* Hepatitis C antibody negative if tested*
        HIV antibody negative if tested* VDRL negative if tested* No known IV drug users HgB &gt; 10.0
        WBC &gt; 3,800 Platelets &gt; 120,000 INR &lt; 2 (verified only if clinically indicated)

        Exclusion Criteria:

        No known neurologic disease 2. No known central nervous system (CNS) metastasis on clinical
        exam 3. No chemotherapy within 1 month 4. No New York Heart Association class III/IV status
        5. No pulmonary disease which limits daily activities 6. No anticoagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Darnell, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mayu Frank, MS ANP</last_name>
    <phone>212-327-7443</phone>
    <email>frankm@rockefeller.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayu Frank, MS ANP</last_name>
      <phone>212-327-7443</phone>
    </contact>
    <investigator>
      <last_name>Robert Darnell, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paraneoplastic; autoimmunity;</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

